Free Trial
NYSEAMERICAN:MAIA

MAIA Biotechnology Q4 2023 Earnings Report

MAIA Biotechnology logo
$1.69 -0.09 (-5.06%)
Closing price 07/18/2025 04:10 PM Eastern
Extended Trading
$1.68 -0.01 (-0.89%)
As of 07/18/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MAIA Biotechnology EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.35
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

MAIA Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MAIA Biotechnology Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Wednesday, March 20, 2024
Conference Call Time
7:00PM ET

Upcoming Earnings

MAIA Biotechnology's Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

MAIA Biotechnology Earnings Headlines

Bitcoin just humbled Jeff Bezos
Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.
See More MAIA Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email.

About MAIA Biotechnology

MAIA Biotechnology (NYSEAMERICAN:MAIA) is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapeutic agents for the treatment of cancer and autoimmune disorders. Leveraging a proprietary protein engineering platform, the company designs multi-specific antibody constructs and immune-modulating fusion proteins that aim to enhance target selectivity, extend half-life, and improve tissue penetration. MAIA’s pipeline encompasses both oncology and immunology programs, with lead candidates advancing through preclinical and early-stage clinical trials.

The company’s flagship oncology programs feature bispecific antibodies directed at complementary immune checkpoints, engineered to potentiate T-cell responses against solid tumors while minimizing off-target effects. In parallel, MAIA is developing targeted therapies for autoimmune indications, including novel cytokine inhibitors and regulatory T-cell modulators designed to restore immune balance in conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. These assets are supported by an integrated discovery engine that combines high-throughput screening, computational biology, and translational biomarkers.

Founded in 2017 as a spin-out from leading academic research institutions, MAIA Biotechnology has built its headquarters and primary research facilities in the Greater Boston area, with an additional biomanufacturing site in the San Francisco Bay Area. The company collaborates with academic centers and contract research organizations across North America and Europe to advance its clinical programs. Strategic partnerships include material transfer agreements for cell-based assays and joint research initiatives focused on novel tumor microenvironment targets.

Under the leadership of CEO Dr. Maria J. Alvarez, a veteran of the biotech industry with over two decades of experience in antibody drug development, MAIA’s management team combines expertise in molecular biology, clinical operations, and regulatory affairs. The board of directors includes industry executives and scientific advisors who have guided multiple biologics through regulatory approval. MAIA Biotechnology continues to pursue value-driving milestones in both its oncology and immunology franchises, aiming to address unmet medical needs through precision immunotherapy.

View MAIA Biotechnology Profile

More Earnings Resources from MarketBeat